{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:02:04Z","timestamp":1789560124913,"version":"build-2803163510"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:p>Within several years after receiving U.S. Food and Drug Administration (FDA) approval in the late 1970s, valproate was shown to increase the risk for major congenital malformations and learning disabilities in the offspring of women who used the drug during pregnancy. Nonetheless, its use in pregnant women has persisted for more than four decades, recently resulting in numerous lawsuits and, in countries other than the United States, criminal indictments of the manufacturers of valproate. The use of valproate in pregnancy persisted and extended beyond its original indication for the treatment of epilepsy. Several recent studies indicate that the drug is more often prescribed to treat pregnant women with bipolar depression and migraine than for seizure control. Especially concerning is the absence of valproate from the list of more than 60 drugs for which the FDA has implemented Risk Evaluation and Mitigation Strategies to prevent or limit untoward consequences associated with specific drugs. Until this step is taken, avoidance of the teratogenic effects of valproate will rely on the vigilance of those caring for women and people with the potential to get pregnant.<\/jats:p>","DOI":"10.1097\/aog.0000000000004893","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T17:00:56Z","timestamp":1659632456000},"page":"408-411","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Valproate Teratogenicity"],"prefix":"10.1097","volume":"140","author":[{"given":"Philip A.","family":"Gruppuso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashid","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli Y.","family":"Adashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"key":"R1-20260916","doi-asserted-by":"crossref","first-page":"m4446","DOI":"10.1136\/bmj.m4446","article-title":"France's drug regulator is indicted for manslaughter over sodium valproate birth defects","volume":"371","author":"Dyer","year":"2020","journal-title":"BMJ"},{"key":"R2-20260916","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.reprotox.2009.02.014","article-title":"Valproic acid in pregnancy: how much are we endangering the embryo and fetus?","volume":"28","author":"Ornoy","year":"2009","journal-title":"Reprod Toxicol"},{"key":"R4-20260916","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S0022-3476(79)80172-9","article-title":"Transmission of valproic acid (Depakene) across the placenta: half-life of the drug in mother and baby","volume":"94","author":"Dickinson","year":"1979","journal-title":"J Pediatr"},{"key":"R5-20260916","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00003495-197713020-00001","article-title":"Sodium valproate: a review of its pharmacological properties and therapeutic efficacy in epilepsy","volume":"13","author":"Pinder","year":"1977","journal-title":"Drugs"},{"key":"R6-20260916","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(80)91159-9","article-title":"Teratogenic potential of valproic acid","volume":"1","author":"Brown","year":"1980","journal-title":"Lancet"},{"key":"R7-20260916","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.04.022","article-title":"Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts","volume":"81","author":"Meador","year":"2008","journal-title":"Epilepsy Res"},{"key":"R8-20260916","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1212\/WNL.0b013e3182574f39","article-title":"Comparative safety of antiepileptic drugs during pregnancy","volume":"78","author":"Hern\u00e1ndez-D\u00edaz","year":"2012","journal-title":"Neurology"},{"key":"R9-20260916","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/jnnp.2003.029132","article-title":"The longer term outcome of children born to mothers with epilepsy","volume":"75","author":"Adab","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R10-20260916","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1212\/WNL.0000000000001772","article-title":"Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study","volume":"85","author":"Tomson","year":"2015","journal-title":"Neurology"},{"key":"R14-20260916","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/AOG.0b013e31816fd910","article-title":"Use of psychiatric medications during pregnancy and lactation. ACOG Practice Bulletin No. 92. American College of obstetricians and Gynecologists","volume":"111","year":"2008","journal-title":"Obstet Gynecol"},{"key":"R15-20260916","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/bmjebm-2018-111068","article-title":"Sodium valproate: who knew what and when? Cumulative meta-analysis gives extra insights","volume":"24","author":"Heneghan","year":"2019","journal-title":"BMJ Evid Based Med"},{"key":"R16-20260916","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/bdra.23147","article-title":"Valproate prescriptions for nonepilepsy disorders in reproductive-age women","volume":"97","author":"Adedinsewo","year":"2013","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"R17-20260916","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1517\/14740338.2015.1084288","article-title":"Foetal safety of old and new antiepileptic drugs","volume":"14","author":"Verrotti","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"R19-20260916","first-page":"180","article-title":"The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines","volume":"20","author":"Fountoulakis","year":"2017","journal-title":"Int J Neuropsychopharmacol"},{"key":"R21-20260916","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1212\/WNL.0000000000008001","article-title":"Declining malformation rates with changed antiepileptic drug prescribing: an observational study","volume":"93","author":"Tomson","year":"2019","journal-title":"Neurology"},{"key":"R22-20260916","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12916-017-0845-1","article-title":"Comparative safety of anti-epileptic drugs during pregnancy: a systematic review and network meta-analysis of congenital malformations and prenatal outcomes","volume":"15","author":"Veroniki","year":"2017","journal-title":"BMC Med"},{"key":"R23-20260916","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.seizure.2016.01.019","article-title":"Prescribing trends for sodium valproate in Ireland","volume":"36","author":"Murphy","year":"2016","journal-title":"Seizure"},{"key":"R24-20260916","doi-asserted-by":"crossref","first-page":"250","DOI":"10.3389\/fpsyt.2020.00250","article-title":"Patterns in psychiatrists' prescription of valproate for female patients of childbearing age with bipolar disorder in Japan: a questionnaire survey","volume":"11","author":"Tachibana","year":"2020","journal-title":"Front Psychiatry"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000004893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:02:25Z","timestamp":1789556545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000004893"}},"subtitle":["A Moving Target"],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004893","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,3]]},"assertion":[{"value":"2022-03-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}